Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome

J Am Acad Dermatol. 2024 Nov 16:S0190-9622(24)03212-2. doi: 10.1016/j.jaad.2024.10.095. Online ahead of print.

¹ Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
² Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
³ Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
⁴ Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: [email protected].

No abstract available

Keywords: Sézary syndrome; T-cell lymphoma; drug response; duvelisib; lenalidomide; mycosis fungoides; oncology.